Pregled bibliografske jedinice broj: 1001373
Comparison of amitriptyline with stabilization splint and placebo in chronic TMD patients: a pilot study.
Comparison of amitriptyline with stabilization splint and placebo in chronic TMD patients: a pilot study. // Acta stomatologica Croatica, 52 (2018), 2; 114-122 doi:10.15644/asc52/2/4 (međunarodna recenzija, članak, znanstveni)
CROSBI ID: 1001373 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Comparison of amitriptyline with stabilization
splint and placebo in chronic TMD patients: a
pilot study.
Autori
Alajbeg, Iva ; Borić Brakus, Ratka ; Brakus, Ivan
Izvornik
Acta stomatologica Croatica (0001-7019) 52
(2018), 2;
114-122
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni
Ključne riječi
Amitriptyline ; Temporomandibular Joint Disorders ; Occlusal Splints ; Chronic Pain
Sažetak
Objective of work The authors conducted a clinical study to evaluate the effectiveness of amitriptyline in treatment of chronic TMD patients and to compare treatment results with stabilization splint. Materials and Methods Twenty-one patients with chronic TMD were included and randomly distributed into 3 groups: patients in Group A received amitriptyline, patients in Group B received placebo, and those in Group C were treated with stabilization splint. Treatment outcomes (pain assessed by a visual analogue scale (VAS), maximal comfortable mouth opening (MCO) and oral health related quality of life (OHIP-14)) were taken at baseline (before treatment), and at 1st, 6th and 12th week of treatment. Results No statistically significant differences between the groups at baseline were found (p>0.05). VAS scores improved significantly in Group A (F=11.326, p=0.002, effect size =0.791) and in group C (F=7.343, p=0.005, effect size=0.647). Mean OHIP- 14 scores decreased significantly only in Group A (F=4.417, p=0.036, effect size =0.596). In Group B, VAS and OHIP-14 scores did not change significantly over time. Subjects in Group C had a significant change in MCO relative to Group A and Group B. Conclusion From this pilot study it can be concluded that the use of low doses of amitriptyline for a period of 12 weeks is effective for pain management and quality of life improvement in chronic TMD patients. Stabilization splint demonstrated superiority in the management of limited mouth opening during the same period.
Izvorni jezik
Engleski
Znanstvena područja
Dentalna medicina
POVEZANOST RADA
Projekti:
HRZZ-IP-2014-09-3070 - Uloga oksidativnog stresa i opiorfina u temporomandibularnim poremećajima (ROStrO-TMD) (Alajbeg, Iva, HRZZ - 2014-09) ( CroRIS)
Ustanove:
Stomatološki fakultet, Zagreb,
Medicinski fakultet, Split
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Emerging Sources Citation Index (ESCI)
- Scopus